185 related articles for article (PubMed ID: 30362279)
1. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM).
Liégeois F; Boyer S; Eymard-Duvernay S; Carrieri P; Kouanfack C; Domyeum J; Maradan G; Ducos J; Mpoudi-Ngolé E; Spire B; Delaporte E; Kuaban C; Vidal L; Laurent C;
BMC Infect Dis; 2020 Jan; 20(1):49. PubMed ID: 31941464
[TBL] [Abstract][Full Text] [Related]
3. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
6. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
7. Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey.
Marinda E; Simbayi L; Zuma K; Zungu N; Moyo S; Kondlo L; Jooste S; Nadol P; Igumbor E; Dietrich C; Briggs-Hagen M
BMC Public Health; 2020 Sep; 20(1):1375. PubMed ID: 32907565
[TBL] [Abstract][Full Text] [Related]
8. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey.
Huerga H; Van Cutsem G; Ben Farhat J; Puren A; Bouhenia M; Wiesner L; Dlamini L; Maman D; Ellman T; Etard JF
BMC Public Health; 2018 Mar; 18(1):303. PubMed ID: 29499668
[TBL] [Abstract][Full Text] [Related]
9. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
[TBL] [Abstract][Full Text] [Related]
10. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon.
Fokam J; Nangmo A; Wandum C; Takou D; Santoro MM; Nlend AN; Ateba FN; Ndombo PK; Kamgaing N; Kamta C; Essiane A; Lambo V; Fokunang C; Mbanya D; Colizzi V; Perno CF; Ndjolo A
AIDS Res Ther; 2020 May; 17(1):14. PubMed ID: 32398107
[TBL] [Abstract][Full Text] [Related]
11. Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey.
Fiorentino M; Sagaon-Teyssier L; Ndiaye K; Suzan-Monti M; Mengue MT; Vidal L; Kuaban C; March L; Laurent C; Spire B; Boyer S;
Womens Health (Lond); 2019; 15():1745506519848546. PubMed ID: 31177929
[TBL] [Abstract][Full Text] [Related]
12. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.
Desta AA; Woldearegay TW; Futwi N; Gebrehiwot GT; Gebru GG; Berhe AA; Godefay H
BMC Infect Dis; 2020 Jan; 20(1):4. PubMed ID: 31898535
[TBL] [Abstract][Full Text] [Related]
13. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.
Gaolathe T; Wirth KE; Holme MP; Makhema J; Moyo S; Chakalisa U; Yankinda EK; Lei Q; Mmalane M; Novitsky V; Okui L; van Widenfelt E; Powis KM; Khan N; Bennett K; Bussmann H; Dryden-Peterson S; Lebelonyane R; El-Halabi S; Mills LA; Marukutira T; Wang R; Tchetgen EJ; DeGruttola V; Essex M; Lockman S;
Lancet HIV; 2016 May; 3(5):e221-30. PubMed ID: 27126489
[TBL] [Abstract][Full Text] [Related]
14. Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal.
Byabene AK; Fortes-Déguénonvo L; Niang K; Manga MN; Bulabula ANH; Nachega JB; Seydi M
Trop Med Int Health; 2017 Jun; 22(6):776-782. PubMed ID: 28407436
[TBL] [Abstract][Full Text] [Related]
15. Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B.
Atanga PN; Ndetan HT; Fon PN; Meriki HD; Muffih TP; Achidi EA; Hoelscher M; Kroidl A
BMC Pregnancy Childbirth; 2018 Oct; 18(1):418. PubMed ID: 30359239
[TBL] [Abstract][Full Text] [Related]
16. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
[TBL] [Abstract][Full Text] [Related]
18. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
Ntamatungiro AJ; Muri L; Glass TR; Erb S; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E;
J Antimicrob Chemother; 2017 Jul; 72(7):2069-2074. PubMed ID: 28387865
[TBL] [Abstract][Full Text] [Related]
19. Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Girometti N; Lander F; McOwan A; Nwokolo N; Boffito M; Whitlock G;
HIV Med; 2020 Oct; 21(9):613-615. PubMed ID: 32869951
[TBL] [Abstract][Full Text] [Related]
20. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
Fatti G; Shaikh N; Eley B; Grimwood A
AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
